NEW YORK (GenomeWeb News) – Myriad Genetics GmbH and Sividon Diagnostics today announced a deal granting Myriad the exclusive rights to co-market Sividon's EndoPredict prognostic test kit for breast cancer patients outside the US.
The deal leverages Myriad's 45-person international commercial team and will "significantly increase" the number of medical specialists and sales professionals supporting EndoPredict, according to the companies.
Myriad Genetics GmbH is the international subsidiary of Myriad Genetics and is based in Zurich.
EndoPredict, a second-generation multigene test kit for patients who have been diagnosed with breast cancer, detects the likelihood of metastases and helps guide treatment with chemotherapy as well as extended anti-hormone therapy. Therapeutic decisions based on EndoPredict results "confer a high level of diagnostic safety," Myriad and Sividon said, adding that in multiple clinical outcome studies with more than 2,200 patients, the test accurately predicted cancer-specific disease progression and metastases.
"Myriad has a significant opportunity to leverage our international presence, and we are pleased to be partnering with Sividon to make EndoPredict even more widely available to patients in Europe and worldwide," Gary King, executive vice president of international operations for Myriad Genetics, said in a statement.
Financial and other terms of the deal were not disclosed.
Based in Cologne, Germany, Sividon was founded in 2010 through a management buyout from Siemens Healthcare Diagnostics and develops methods for molecular pathology laboratories to improve care for cancer patients.